NASDAQ:ERAS Erasca (ERAS) Stock Price, News & Analysis $2.49 +0.04 (+1.63%) (As of 08:53 AM ET) Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends About Erasca Stock (NASDAQ:ERAS) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Erasca alerts:Sign Up Key Stats Today's Range$2.49▼$2.4950-Day Range$2.45▼$3.2352-Week Range$1.64▼$3.45Volume1,622 shsAverage Volume1.61 million shsMarket Capitalization$703.99 millionP/E RatioN/ADividend YieldN/APrice Target$5.90Consensus RatingModerate Buy Company OverviewErasca, Inc., a clinical-stage precision oncology company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead product is naporafenib which is in phase 1b trial for patients with RAS Q16X solid tumors and plans to initiate a pivotal Phase 3 trial for patients with NRASm melanoma. It also develops ERAS-007, an oral inhibitor of ERK1/2 for the treatment of non-small cell lung and colorectal cancer, and advanced gastrointestinal malignancies; and ERAS-601, an oral SHP2 inhibitor for patients with advanced or metastatic solid tumors. In addition, it is developing ERAS-801, a central nervous system-penetrant EGFR inhibitor which is in phase 1 clinical trials for the treatment of patients with recurrent glioblastoma multiforme. The company entered into license agreement with Novartis to develop, manufacture, use, and commercialize naporafenib; Katmai Pharmaceuticals, Inc. to develop, manufacture, use, and commercialize ERAS-801 and certain other related compounds; and NiKang Therapeutics, Inc. to develop and commercialize ERAS-601 and certain other related compounds. Erasca, Inc. was incorporated in 2018 and is headquartered in San Diego, California.Read More… Erasca Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks40th Percentile Overall ScoreERAS MarketRank™: Erasca scored higher than 40% of companies evaluated by MarketBeat, and ranked 688th out of 945 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.4 / 5Analyst RatingModerate Buy Consensus RatingErasca has received a consensus rating of Moderate Buy. The company's average rating score is 2.80, and is based on 4 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageErasca has only been the subject of 3 research reports in the past 90 days.Read more about Erasca's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Erasca are expected to grow in the coming year, from ($0.73) to ($0.61) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Erasca is -3.06, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Erasca is -3.06, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioErasca has a P/B Ratio of 1.21. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Short Interest0.0 / 5Short Interest LevelBearish Percentage of Shares Shorted19.73% of the float of Erasca has been sold short.Short Interest Ratio / Days to CoverErasca has a short interest ratio ("days to cover") of 18.1, which indicates bearish sentiment.Change versus previous monthShort interest in Erasca has recently increased by 0.25%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldErasca does not currently pay a dividend.Dividend GrowthErasca does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted19.73% of the float of Erasca has been sold short.Short Interest Ratio / Days to CoverErasca has a short interest ratio ("days to cover") of 18.1, which indicates bearish sentiment.Change versus previous monthShort interest in Erasca has recently increased by 0.25%, indicating that investor sentiment is decreasing. News and Social Media2.1 / 5News Sentiment0.75 News SentimentErasca has a news sentiment score of 0.75. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.60 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Erasca this week, compared to 2 articles on an average week.MarketBeat FollowsOnly 2 people have added Erasca to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Company Ownership3.3 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Erasca insiders have not sold or bought any company stock.Percentage Held by Insiders21.50% of the stock of Erasca is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions67.78% of the stock of Erasca is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Erasca's insider trading history. Receive ERAS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Erasca and its competitors with MarketBeat's FREE daily newsletter. Email Address ERAS Stock News HeadlinesErasca initiated with a Buy at JefferiesNovember 19, 2024 | markets.businessinsider.comJefferies Initiates Coverage of Erasca (ERAS) with Buy RecommendationNovember 19, 2024 | msn.comNo one’s talking about these Trump tradesAs you likely know, the “Trump bump” launched stocks to record highs after he secured his second reelection bid. Now, Trump and his team are coming to gut government regulation – and it’s going to create some incredible market opportunities. But while the masses chase large-cap tech and so-called AI stocks, a small circle of traders are using a strange but tactical method to find a pool of “hidden Trump trades.”December 23, 2024 | Insiders Exposed (Ad)Bank of America Securities Sticks to Its Hold Rating for Erasca (ERAS)November 15, 2024 | markets.businessinsider.comErasca, Inc. Reports Strong Progress in Oncology PipelineNovember 15, 2024 | markets.businessinsider.comErasca, Inc.: Erasca Reports Third Quarter 2024 Business Updates and Financial ResultsNovember 13, 2024 | finanznachrichten.deErasca (ERAS) Gets a Buy from Morgan StanleyNovember 13, 2024 | markets.businessinsider.comErasca’s Innovative Naporafenib Shows Promise in NRAS-mutant Melanoma, Garnering Buy Rating from AnalystNovember 13, 2024 | markets.businessinsider.comSee More Headlines ERAS Stock Analysis - Frequently Asked Questions How have ERAS shares performed this year? Erasca's stock was trading at $2.13 on January 1st, 2024. Since then, ERAS shares have increased by 19.2% and is now trading at $2.54. View the best growth stocks for 2024 here. How were Erasca's earnings last quarter? Erasca, Inc. (NASDAQ:ERAS) announced its quarterly earnings results on Tuesday, November, 12th. The company reported ($0.11) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.17) by $0.06. When did Erasca IPO? Erasca (ERAS) raised $262 million in an IPO on Thursday, July 15th 2021. The company issued 17,500,000 shares at $14.00-$16.00 per share. Who are Erasca's major shareholders? Top institutional shareholders of Erasca include Frazier Life Sciences Management L.P. (6.86%), State Street Corp (2.13%), PFM Health Sciences LP (1.73%) and Geode Capital Management LLC (1.59%). Insiders that own company stock include Jonathan E Lim, Bihua Chen, Alexander W Casdin and Valerie Denise Harding Start. View institutional ownership trends. How do I buy shares of Erasca? Shares of ERAS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Erasca own? Based on aggregate information from My MarketBeat watchlists, some other companies that Erasca investors own include Waste Connections (WCN), The RMR Group (RMR), AUO (AUOTY), American Water Works (AWK), DiamondRock Hospitality (DRH), iShares Micro-Cap ETF (IWC) and Triple Flag Precious Metals (TFPM). Company Calendar Last Earnings11/12/2024Today12/23/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:ERAS CUSIPN/A CIK1761918 Webwww.erasca.com Phone858-465-6511FaxN/AEmployees126Year FoundedN/APrice Target and Rating Average Stock Price Target$5.90 High Stock Price Target$8.00 Low Stock Price Target$3.50 Potential Upside/Downside+132.3%Consensus RatingModerate Buy Rating Score (0-4)2.80 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)($0.83) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-125,040,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-42.26% Return on Assets-34.97% Debt Debt-to-Equity RatioN/A Current Ratio11.00 Quick Ratio11.00 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$2.10 per share Price / Book1.21Miscellaneous Outstanding Shares282,727,000Free Float221,941,000Market Cap$718.13 million OptionableOptionable Beta1.20 10 Best Cheap Stocks to Buy NowMarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.Get This Free Report This page (NASDAQ:ERAS) was last updated on 12/23/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredWe recommended Palantir in 2021, now we’re recommending this...My research indicates there is only one investment that can meet AI's unprecedented demand for energy.Behind the Markets | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowIt’s here. This is the moment we’ve been waiting for. The next 3-6 months in crypto will be absolutely life...Crypto Swap Profits | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Erasca, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Erasca With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.